What is Better Than A Mammogram
What is better than a Mammogram and can Help The Obama Administration Health Reform Act (Obama Care) Robert Graham Ph.D. and Barron’s Medical Journal Reporting from GeorgeTown University February 12, 2014 
Washington DC ( AP )--- What is Genomics? Genomics is a new and fast expanding area of biology encompassing high throughput or large scale experimentation at the whole genome level, and the organization, analysis and interpretation of the huge amount of data emerging from genome projects. Major new technologies have evolved recently that enable experimentation at the whole genome level, and more novel technologies are currently being developed. 
This volume describes in detail the new technology necessary to study the entire genome in a holistic manner and all the high throughput and large-scale experimental methodologies currently being used in genomic science. In addition the authors describe the progress of the newest technologies that are currently being developed. Written by experts in the field, this concise yet informative volume covers all aspects of technology pertaining to genomic studies. It is an essential book for anyone involved in genomic science.
This volume describes in detail the new technology necessary to study the entire genome in a holistic manner and all the high throughput and large-scale experimental methodologies currently being used in genomic science. In addition the authors describe the progress of the newest technologies that are currently being developed. Written by experts in the field, this concise yet informative volume covers all aspects of technology pertaining to genomic studies. It is an essential book for anyone involved in genomic science.
During the five year screening period, 666 invasive breast cancers were diagnosed in the mammography arm (n=44 925 participants) and 524 in the controls (n=44 910), and of these, 180 women in the mammography arm and 171 women in the control arm died of breast cancer during the 25 year follow-up period. The overall hazard ratio for death from breast cancer diagnosed during the Brought To You By The Houston Ballet Ball:
screening period associated with mammography was 1.05 (95% confidence interval 0.85 to 1.30). The findings for women aged 40-49 and 50-59 were almost identical. During the entire study period, 3250 women in the mammography arm and 3133 in the control arm had a diagnosis of breast cancer, and 500 and 505, respectively, died of breast cancer.
Thus the cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm (hazard ratio 0.99, 95% confidence interval 0.88 to 1.12). After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis.
screening period associated with mammography was 1.05 (95% confidence interval 0.85 to 1.30). The findings for women aged 40-49 and 50-59 were almost identical. During the entire study period, 3250 women in the mammography arm and 3133 in the control arm had a diagnosis of breast cancer, and 500 and 505, respectively, died of breast cancer.
Thus the cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm (hazard ratio 0.99, 95% confidence interval 0.88 to 1.12). After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis.
Conclusion Annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available.
Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.
Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.
Breast Cancer patients can aligning environmental science with regulation, Genomics in Regulatory Ecotoxicology: Applications and Challenges presents the first in-depth set of recommendations published in the open literature focused specifically on how genomics data could be used in regulatory ecotoxicology. The book develops a conceptual framework of how genomics data can most effectively impact current approaches for ecological risk assessments. It also identifies biomarkers of exposure and effects for both lab and field monitoring studies and provides a basis for the extrapolation of chemical effects across species. It explores exactly how data generated from new genomics technologies might impact or benefits risk assessment. Features: Identifies biomarkers of exposure and effects for use in both lab and field studies, Provides a basis for the extrapolation of chemical effects across species, Describes current and planned applications of genomic technologies to screening assays for use in ecotoxicology decision-making, including risk assessment, Focuses on the development and application of genomics to tiered testing, including how genomics may be used to support streamlining of current chemical testing programs, Highlights the application of genomic technologies to complex mixtures of contaminants in the environment, such as sites requiring remediation.
Breast Cancer Genomics in Regulatory Ecotoxicology: Applications and Challenges is one of many SETAC publications that offer timely, innovative, and critically reviewed perspectives on current topics relating to broad environmental toxicology and chemistry issues. SETAC assumes an active 
leadership in the development of educational programs and publishes the peer-reviewed, international journals Environmental Toxicology and Chemistry and Integrated Environmental Assessment and Management.
leadership in the development of educational programs and publishes the peer-reviewed, international journals Environmental Toxicology and Chemistry and Integrated Environmental Assessment and Management.
Dr. Kalager, an epidemiologist and screening researcher at the University of Oslo and the Harvard School of Public Health, said there was a reason the results were unlike those of earlier studies. With better treatments, like tamoxifen, it was less important to find cancers early. Also, she said, women in the Canadian study were aware of breast cancer and its dangers, unlike women in earlier studies who were more likely to ignore lumps.
“It might be possible that mammography screening would work if you don’t have any awareness of the disease,” she said.
Sam Houston Biotech has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.
Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
Sam Houston Biotech minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
In the United States, about 37 million mammograms are performed annually at a cost of about $100 per mammogram. Nearly three-quarters of women age 40 and over say they had a mammogram in the past year. Ninety percent of women ages fifty to sixty nine years of age in several European countries have had at least one mammogram.
No comments:
Post a Comment